Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

Michael O'Riordan

June 25, 2025

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

First PCIs Preceded by Many Modifiable Risk Factors: Registry Data

L.A. McKeown

June 16, 2021

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Heart Disease Deaths Decline Over Last 50 Years, but Not Across the Board

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

First PCIs Preceded by Many Modifiable Risk Factors: Registry Data

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content